Strides Pharma Science Ltd Share Price
(STAR)
₹651.9
as on 04:01PM, 29 Apr 2025
🔔 Acquisition Alert
Strides Pharma's US subsidiary acquires four approved ANDAs from Nostrum Laboratories for $2.075 million, expanding its portfolio in niche therapeutic segments.
Strides Pharma Science Ltd Performance
Day's Low
Day's High
₹648.4Day's Price Range₹674.1552 Week's Low
52 Week's High
₹513.0552-Week Price Range₹1,675
| Returns % | |
| 1 Month Return | -2.23 % |
| 3 Month Return | -1.02 % |
| 1 Year Return | -27.25 % |
| Market Stats | |
| Previous Close | ₹663.35 |
| Open | ₹666.50 |
| Volume | 2.76L |
| Upper Circuit | ₹796.00 |
| Lower Circuit | ₹530.70 |
| Market Cap | ₹6,008.09Cr |
Strides Pharma Science Ltd Fundamentals
P/E Ratio
37.91
PEG Ratio
1.72
Market Cap
₹6,008.09 Cr
P/B Ratio
2.02
EPS
-4.49599698514042
Dividend Yield
0.32
Sector
Pharmaceuticals
ROE
1.87
Mutual Fund Holdings of Strides Pharma Science Ltd
Strides Pharma Science Ltd Analyst Rating
based on 2 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 2 analysts offering long term price targets for Strides Pharma Science Ltd. An average target of ₹1472
Source: S&P Global Market Intelligence
Strides Pharma Science Ltd Share analysis
Strides Pharma Science Ltd price forecast by 2 analysts
Upside of125.80%
High
₹1874
Target
₹1472.00
Low
₹1070
Strides Pharma Science Ltd target price ₹1472, a slight upside of 125.8% compared to current price of ₹651.9. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Strides Pharma Science Ltd revenue growth forecast
Expected growth rate Q1, FY2027:42.39%
Forecast
Actual
Including amortisation and stock based compensations
Strides Pharma Science Ltd EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - 30 Apr
08:24 AM
-Strides Pharma's US unit acquires four approved ANDAs from Nostrum Laboratories for $2.075 million, expanding its product portfolio.
Key events for Strides Pharma Science Ltd
Strides Pharma Expands Portfolio with ANDA Acquisition - 29 Apr, 2025
Strides Pharma Science's subsidiary has acquired four ANDAs from Nostrum Laboratories for $2.07 million, enhancing its portfolio in niche and difficult-to-manufacture products. The acquisition includes products for treating UTIs, pain management, and more, with a cumulative market size of approximately $57 million.Strides Pharma Launches New Subsidiary for Innovation - 11 Apr, 2025
Strides Pharma Science Limited has incorporated a new wholly owned subsidiary, Pivot Path, to enhance life sciences and digital innovation. This entity will focus on outsourcing and business support services in the pharmaceutical sector, aligning with a previously announced Scheme of Arrangement. The incorporation aims to leverage advanced technologies and domain expertise, although operations have yet to commence.Strides Pharma Recalls Testosterone Gel Over Safety Concerns - 04 Apr, 2025
Strides Pharma has voluntarily recalled over 440,000 cartons of Testosterone Gel in the US after detecting benzene, a carcinogenic substance, raising significant health concerns.
Insights on Strides Pharma Science Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 27.77% to 29.65% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 18.18 Cr → 87.95 Cr (in ₹), with an average increase of 31.6% per quarter
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 26.82% to 28.30% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 34.9%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 75.4%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 10.86% to 8.89% in Mar 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 1.19K Cr → 1.16K Cr (in ₹), with an average decrease of 2.9% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 28.48% to 28.32% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 6 months, STAR stock has moved down by -55.6%
Strides Pharma Science Ltd Financials
Strides Pharma Science Ltd Index Inclusions
Strides Pharma Science Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 28.3% | 0.00 | |
| Foreign Institutions | 28.32% | 0.00 | |
| Mutual Funds | 8.89% | 0.00 | |
| Retail Investors | 29.65% | 0.00 | |
| Others | 4.84% | 0.00 |
Strides Pharma Science Ltd Key Indicators
Strides Pharma Science Ltd Valuation
Strides Pharma Science Ltd in the last 5 years
Lowest (-409.06x)
July 5, 2021
Today (37.91x)
April 29, 2025
Industry (54.77x)
April 29, 2025
Highest (6306.63x)
September 27, 2024
Strides Pharma Science Ltd Earnings and Dividends
Strides Pharma Science Ltd Earnings Results
Strides Pharma Science Ltd’s net profit jumped 77.07% since last year same period to ₹87.95Cr in the Q3 2024-2025. On a quarterly growth basis, Strides Pharma Science Ltd has generated 22.42% jump in its net profits since last 3-months.
Read More about Earnings ResultsStrides Pharma Science Ltd Dividends May,2024
In the quarter ending March 2024, Strides Pharma Science Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.61%.
Read More about Dividends
Strides Pharma Science Ltd Technicals Summary
Bearish
Neutral
Bullish
Strides Pharma Science Ltd is currently in a Bearish trading position according to technical analysis indicators.
Strides Pharma Science Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹6,008.09 Cr | 9.47% | 0.66 | -₹95 Cr | ₹4,051 Cr | |
| NA | ₹147.07 Cr | 35.43% | 0.62 | NA | NA | |
| NA | ₹5,411.31 Cr | 432.02% | 0.50 | ₹33 Cr | ₹204 Cr | |
| NA | ₹1,510.04 Cr | 381.87% | 0.52 | NA | NA | |
| NA | ₹3,596.41 Cr | 157.18% | 0.51 | NA | NA |
About Strides Pharma Science Ltd
Revenue: ₹1,153.67Cr as on December 2024 (Q4 24)
Net Profit: ₹90.04Cr as on December 2024 (Q4 24)
Listing date: 02 Feb, 2000
Chairperson Name: Arun Kumar
| Organisation | Strides Pharma Science Ltd |
| Headquarters | Bangaluru |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Strides Pharma Science Ltd
What is Strides Pharma Science Ltd price today?
Strides Pharma Science Ltd share price today stands at ₹651.9, Open: ₹666.5, Previous Close: ₹663.35, High: ₹674.15, Low: ₹648.4, 52 Week High: ₹1675, 52 Week Low: ₹513.05.
How to Buy Strides Pharma Science Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Strides Pharma Science Ltd shares
What are today's traded volumes of Strides Pharma Science Ltd?
Today's traded volume of Strides Pharma Science Ltd(STAR) is 2.76L.
What is today's market capitalisation of Strides Pharma Science Ltd?
Today's market capitalisation of Strides Pharma Science Ltd(STAR) is ₹6008.09Cr.
What is the 52 Week High and Low Range of Strides Pharma Science Ltd?
How much percentage Strides Pharma Science Ltd is down from its 52 Week High?
Strides Pharma Science Ltd (STAR) share price is ₹651.9. It is down -61.08% from its 52 Week High price of ₹1675
How much percentage Strides Pharma Science Ltd is up from its 52 Week low?
Strides Pharma Science Ltd (STAR) share price is ₹651.9. It is up 27.06% from its 52 Week Low price of ₹513.05